Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.

Related Articles

Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.

J Pathol Transl Med. 2017 May;51(3):224-241

Authors: Jeon YK, Yoon SO, Paik JH, Kim YA, Shin BK, Kim HJ, Cha HJ, Kim JE, Huh J, Ko YH, Hematopathology Study Group of the Korean Society of Pathologists, Molecular Pathology Study Group of Korean Society of Pathologists

Abstract
Molecular pathologic testing plays an important role for the diagnosis, prognostication and decision of treatment strategy in lymphoproliferative disease. Here, we briefly review the molecular tests currently used for lymphoproliferative disease and those which will be implicated in clinical practice in the near future. Specifically, this guideline addresses the clonality test for B- and T-cell proliferative lesions, molecular cytogenetic tests for malignant lymphoma, determination of cell-of-origin in diffuse large B-cell lymphoma, and molecular genetic alterations incorporated in the 2016 revision of the World Health Organization classification of lymphoid neoplasms. Finally, a new perspective on the next-generation sequencing for diagnostic, prognostic, and therapeutic purpose in malignant lymphoma will be summarized.

PMID: 28535584 [PubMed - in process]

http://ift.tt/2qVV9ol